A precursor of PSA detects more aggressive prostate cancer

July 11, 2003

Washington, DC - An inactive precursor form of PSA, prostate specific antigen, may prove better than the current standard of testing at detecting prostate cancer and identifying more aggressive forms of the disease, according to a study presented today at the 94th Annual Meeting of the American Association for Cancer Research (AACR).

PSA, an enzyme normally secreted by the prostate, is a well-known marker used to detect the presence of prostate cancer. As prostate cancer develops, a greater amount of PSA is released into the blood stream. Current PSA tests measure "free" and "bound" PSA, yet often fail to distinguish between slow growing cancers, which may take years to become life-threatening, and more aggressive cancers, which are likely to grow quickly and spread, requiring immediate surgery and other therapy. PSA consists of several molecular forms including proPSA, which is a precursor form of the enzyme that has been shown to be a more cancer-specific marker of prostate cancer.

"By measuring the proportion of proPSA relative to PSA, we were able to identify the men with earlier aggressive cancer who might not have otherwise been detected until it was too late to administer effective treatment," according to Stephen Mikolajczyk, staff research scientist at Beckman Coulter, Inc., San Diego. "These results may significantly alter the current standard for screening of prostate cancer by enabling detection at a cutoff below 4 nanogram(ng)/ml and reducing the number of unnecessary biopies."

The study retrospectively analyzed 1,091 blood serum specimens from men enrolled in prostate cancer screening studies who had undergone prostate biopsy (PSA 2-4 ng/ml: 320 benign, 235 cancer; PSA 4-10 ng/ml: 315 benign, 221 cancer). Throughout the 2 to 10 ng/ml range, levels of proPSA were measured using research immunoassays, developed by Mikolajczyk and his team, to determine the efficacy for detecting cancer and the ability of identifying more aggressive forms of the disease. (These assays are for research use only and are not intended for diagnostic procedures.)

Analysis of the data shows that proPSA was a better marker than the other forms of PSA - total, free, and complex - at detecting prostate cancer throughout the 2-10 ng/ml PSA range. ProPSA superiority was most pronounced in the 2-4 ng/ml range. In addition, proPSA more accurately identified aggressive forms of cancer by Gleason Score discrimination in the 2 - 4 and 4 -10 ng/ml range. The commercially available assays for free, total, and complex PSA were not effective in predicting cancer below 4ng/ml. The Gleason Score is a measure of the disruption of normal tissue architecture caused by cancer cells and is given as a scale from 1-10 after microscopic examination.

Biopsies of the prostate are usually not performed in patients with a PSA score less than 4 ng/ml. Instead, physicians often wait and conduct a follow-up exam six months to a year later. A PSA higher than 10 ng/ml indicates a high risk of cancer and the need for a biopsy to confirm the presence of the disease. For PSA results in the "grey zone" - between 4 to 10 ng/ml - a biopsy is recommended, but there is only a 30 - 40 percent chance of cancer. Since as many as 25 percent of men with PSA values below 4 ng/ml may also have prostate cancer, the cutoff mark of 4 ng/ml is controversial. Many physicians believe the cutoff should be lowered to 2 or 3 ng/ml, including study co-investigator William Catalona, MD, of Northwestern Feinberg School of Medicine, Chicago.

"As we see it now, proPSA will augment the current PSA tests by improving detection of prostate cancer, which may result in fewer cancer-related deaths in men and improved quality of life for survivors," says Mikolajczyk. ProPSA was first discovered in serum by Mikolajczyk and his team of co-workers at Beckman Coulter in 1997. Prostate cancer is the second leading cause of cancer death among men in the United States. The American Cancer Society estimates that in 2003 there will be about 220,900 new cases of prostate cancer, causing more than 28,000 deaths.
-end-
Founded in 1907, the American Association for Cancer Research (AACR) is a professional society of more than 20,000 laboratory and clinical scientists engaged in cancer research in the United States and more than 60 other countries. AACR's mission is to accelerate the prevention and cure of cancer through research, education, communication and advocacy. Its principal activities include the publication of five major peer-reviewed scientific journals (Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention). AACR's annual meeting attracts more than 12,000 participants who share new and significant discoveries in the cancer field, and the AACR's specialty meetings throughout the year focus on all the important areas of basic, translational and clinical cancer research. Contact: Warren Froelich/AACR
froelich@aacr.org
215/440-9300


Aimee Frank/Spectrum Science
amf@spectrumscience.com
202/955-6222

In Washington, DC: (7/11-7/14)
Washington Convention Center
202/249-4060


American Association for Cancer Research

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.